Cohen Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Cohen Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-2,000	Closed	-$64K	–	232
2017 Q1	$64K	Sell	2,000 -118,700	-98%	-$4.05M	0.02%	162
2016 Q4	$4.38M	Sell	120,700 -37,000	-23%	-$1.48M	1.19%	34
2016 Q3	$7.26M	Sell	157,700 -5,150	-3%	-$269K	2.03%	15
2016 Q2	$8.18M	Buy	162,850 +4,800	+3%	+$256K	2.38%	12
2016 Q1	$10.4M	Hold	158,050	–	–	3.13%	4
2015 Q4	$10.4M	Hold	158,050	–	–	3.13%	4
2015 Q3	$8.92M	Hold	158,050	–	–	2.67%	6
2015 Q2	$9.34M	Hold	158,050	–	–	2.41%	6
2015 Q1	$9.85M	Hold	158,050	–	–	2.51%	5
2014 Q4	$9.09M	Hold	158,050	–	–	2.36%	6
2014 Q3	$8.49M	Hold	158,050	–	–	2.27%	7
2014 Q2	$8.29M	Hold	158,050	–	–	2.14%	8
2014 Q1	$8.35M	Hold	158,050	–	–	2.25%	7
2013 Q4	$6.33M	Hold	158,050	–	–	1.79%	17
2013 Q3	$5.97M	Sell	158,050 -4,500	-3%	-$176K	1.84%	14
2013 Q2	$6.37M	Buy	+162,550	New	+$6.33M	2.03%	9

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Cohen Capital Management's TEVA Position: Q2 2017 in Review

Cohen Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2017, closing a stake of 2,000 shares — an estimated $64K sold.

Cohen Capital Management first reported a position in TEVA in Q2 2013 and held it in 16 quarters. The position peaked at $10.4M in Q1 2016. 649 funds tracked by Wall St. Rank hold TEVA as of Q2 2017.

Cohen Capital Management reported no remaining Teva Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Cohen Capital Management sold 2,000 Teva Pharmaceuticals shares in Q2 2017, an estimated $64K.
Cohen Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 16 quarters.
Cohen Capital Management's Teva Pharmaceuticals position peaked at $10.4M in Q1 2016.
649 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2017.

Based on Cohen Capital Management's 13F filing for Q2 2017, filed 12 Jul 2017.